A Study to Compare the Effectiveness of a Drug That Suppresses the Immune System Called Thymoglobulin® in Preventing the Development of a Disease That Affects the Majority of Heart Transplant Recipients Called Cardiac Allograft Vasculopathy (CAV)
This study is not yet open for participant recruitment.
Verified May 2010 by Cedars-Sinai Medical Center
Sponsor:
Cedars-Sinai Medical Center
Collaborator:
Genzyme
Information provided by:
Cedars-Sinai Medical Center
ClinicalTrials.gov Identifier:
NCT01157949
First received: July 7, 2010
Last updated: NA
Last verified: May 2010
History: No changes posted
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is not yet open for participant recruitment. |
|---|---|
| Estimated Study Completion Date: | No date given |
| Estimated Primary Completion Date: | November 2013 (Final data collection date for primary outcome measure) |